2C10.1

ICD-11 MMS 2026-01

Neuroendocrine neoplasms of pancreas

Description

A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumours (low and intermediate grade) and neuroendocrine carcinomas (high grade).

Coding note from above levels

For use of this category, reference should be made to the mortality coding rules and guidelines in the Reference Guide.

Index terms

  • Neuroendocrine neoplasms of pancreas
  • carcinoma of islet cell of pancreas
  • malignant islet cell tumour of unspecified site
Show allHide
  • malignant tumour, islet cell of pancreas
  • neuroendocrine pancreatic cancer
  • Neuroendocrine tumours of pancreas
  • Malignant alpha cell tumour of pancreas
  • Malignant alpha cell tumour, unspecified site
  • Malignant beta cell tumour of pancreas
  • Malignant beta cell tumour, unspecified site
  • Malignant G cell tumour of pancreas
  • Malignant G cell tumour, unspecified site
  • Neuroendocrine carcinoma of pancreas
  • Insulinoma
  • Insulinoma of unspecified site
  • Malignant insulinoma of unspecified site
  • Glucagonoma
  • glucagonoma NOS
  • glucagonoma unspecified site
  • Gastrinoma
  • Gastrinoma of unspecified site
  • VIPoma
  • Increased secretion from endocrine pancreas of vasoactive-intestinal polypeptide
  • Pancreatic hypersecretion of vasoactive intestinal peptide
  • Verner–Morrison syndrome
  • WDHA - [watery diarrhea, hypokalemia, and achlorhydria] syndrome
  • WDHA syndrome
  • Somatostatinoma
  • Increased secretion from endocrine pancreas of somatostatin
  • Pancreatic hypersecretion of somatostatin
  • Other neuroendocrine tumour of pancreas
  • GRFoma
  • GRF - [growth hormone releasing factor] tumour
  • Growth hormone releasing factor tumour
  • Increased secretion from endocrine pancreas of growth hormone-releasing hormone
  • Pancreatic hypersecretion of growth hormone releasing factor
  • PPoma
  • Hypersecretion of pancreatic polypeptide
  • Increased secretion from endocrine pancreas of pancreatic polypeptide
  • Pancreatic polypeptidoma

Exclusions from above levels

  • 2D81 – Malignant neoplasm metastasis in pancreas
  • http://id.who.int/icd/entity/1965082709 – Malignant mesenchymal neoplasms
  • http://id.who.int/icd/entity/111033337 – Malignant neoplasm metastasis in digestive system
Show allHide
  • http://id.who.int/icd/entity/794095161 – Malignant neoplasms of lip, oral cavity or pharynx
  • http://id.who.int/icd/entity/879154182 – Neoplasms of central nervous system or related structures
  • http://id.who.int/icd/entity/944754984 – Neoplasms of haematopoietic or lymphoid tissues

Sibling codes

  • 2C10.0 – Adenocarcinoma of pancreas
  • 2C10.Y – Other specified malignant neoplasms of pancreas
  • 2C10.Z – Malignant neoplasm of pancreas, unspecified

Foundation entity

Neuroendocrine neoplasms of pancreas – http://id.who.int/icd/entity/1421495979

Allowed postcoordination axes

Part of: 2C10: Malignant neoplasm of pancreas › 02: Neoplasms